Relapse Rate and Time to First Relapse were Improved with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients with Relapsing Multiple Sclerosis (RMS) By admin / 04/05/2022
Disability Improvements with Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Evaluations from the Phase 3 ULTIMATE I and II Studies By admin / 04/03/2022
Ublituximab Treatment is Associated with a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results from the Ultimate I and Ultimate II Phase 3 Studies of Ublituximab vs Teriflunomide in Relapsing Multiple Sclerosis (RMS) By admin / 04/03/2022
Infusion-Related Reactions (IRRs) with Ublituximab in Patients with Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses from the Phase 3 ULTIMATE I and II Studies By admin / 04/03/2022
Reduction in T1 Hypointense Lesions with Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients with Relapsing Multiple Sclerosis By admin / 02/24/2022
Neutralizing Antibodies and Antidrug Antibodies in the Ublituximab Phase 3 ULTIMATE I & II Studies in Relapsing Multiple Sclerosis By admin / 02/24/2022
Favorable Outcomes for Patients with Co-morbidities or Concomitant Medications Treated with U2: A Retrospective Analysis of UNITY-CLL Phase 3 Trial By admin / 12/13/2021
Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) by Treatment Status: A Sub-analysis of the Phase 3 UNITY-CLL Study By admin / 12/13/2021
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): a Minimal Residual Disease (MRD)-driven, Time-limited Approach By admin / 12/12/2021
